Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation.

摘要: Background The aim of this pilot study was to evaluate the efficacy and safety lamivudine therapy in hepatitis B virus (HBV)-positive/DNA-positive renal transplant recipients. Methods Six HBV DNA-positive cadaveric recipients ranging age from 49+/-6 years were administered lamivudine, at 100 mg/day for a period least 6 months, on compassionate-use basis. Lamivudine is (-) enantiomer 3'-thiacytidine, which known be potent inhibitor replication. All patients but one cyclosporine-based immunosuppression. Results mean serum creatinine 134+/-44 micromol/L. duration infection 230+/-54 months (156-288). had high alanine aminotransferase levels (122+/-52 IU/L; range, 45-243). Histological evaluation showed presence either chronic active (n=4) or cirrhosis (n=2). e antigen negative/hepatitis antibody positive, none coinfected with C D virus. Conclusions associated (i) normalization four five when these increased beginning (n=5); (ii) rapid disappearance DNA (detected by hybridization) all patients; (iii) negativity polymerase chain reaction (iv) no change function proteinuria present (one patient). Finally, adverse effects noted. When stopped after it biochemical virological relapse within weeks that followed. therefore resumed patients.